Familial combined hyperlipidemia (FCHL) is a common genetic dyslipidemia predisposing to premature coronary artery disease. Characteristics of the disorder include hypertriglyceridemia, hypercholesterolemia, and elevated apolipoprotein B (apoB). The etiology is complex, with multiple environmental and genetic influences.; One powerful approach to the dissection of a complex trait is to use animal models. We identified a mutant mouse strain, HcB-19/Dem, which shares features with FCHL, including hypertriglyceridemia, hypercholesterolemia, elevated plasma apoB, and increased secretion of very low density lipoproteins. The hyperlipidemia results from spontaneous mutation at a locus, Hyplip1, which maps to distal mouse Chromosome 3. Importantly, this region is syntenic to a FCHL locus on human 1q21–q23.; In order to identify the Hyplip1 gene, a positional cloning approach was employed. First, the Hyplip1 location was narrowed to ∼160 kilobases by fine mapping. Next, a bacterial artificial chromosome (BAC) contig was constructed. Finally, select BACs were sequenced to identify candidate genes that were analyzed for expression or sequence differences by Northern and DNA sequence analyses. In HcB-19/Dem, decreased mRNA levels were observed for a gene previously described as vitamin D3 up-regulated protein 1 (Vdup1). Sequencing of Vdup1 RT-PCR products revealed a nonsense mutation present in the hyperlipidemic HcB-19/Dem strain but absent in the normolipidemic control strain from which it was derived. No differences were found for any other candidate genes.; The Vdup1 protein, also known as thioredoxin interacting factor (Thif), binds to and inhibits thioredoxin, a ubiquitous protein with disulfide reducing activity that plays a role in multiple cellular processes. The nonsense mutation in HcB-19/Dem mice occurs at position 337 of the 1456 bp cDNA (Genbank AF173681), corresponding to amino acid 97 of the 395 amino acid protein. The truncated Vdup1 resulting from the Hyplip1 nonsense mutation will be unable to bind and inhibit thioredoxin, since residues 134–395 are crucial for this interaction.; In addition to combined hyperlipidemia, HcB-19/Dem mice also exhibit hyperketonemia, hypoglycemia, and increased plasma lactate, free fatty acid, and unesterified cholesterol levels. Preliminary evidence also indicates an increased susceptibility to hepatic carcinoma. These results reveal a novel pathway, of potential clinical significance, influencing both lipid and carbohydrate metabolism.
展开▼
机译:家族性合并高脂血症(FCHL)是一种常见的遗传性血脂异常,易患早发性冠状动脉疾病。该疾病的特征包括高甘油三酯血症,高胆固醇血症和载脂蛋白B(apoB)升高。病因复杂,具有多种环境和遗传影响。解剖复杂性状的一种有效方法是使用动物模型。我们确定了突变的小鼠品系HcB-19 / Dem italic>,与FCHL具有相同的功能,包括高甘油三酯血症,高胆固醇血症,血浆apoB升高以及极低密度脂蛋白的分泌增加。高脂血症是由 Hyplip1 italic>基因座的自发突变引起的,该基因突变映射到小鼠远端染色体3。重要的是,该区域与人类1q21–q23上的FCHL基因座是同义的。为了鉴定 Hyplip1 italic>基因,采用了位置克隆方法。首先,通过精细映射将 Hyplip1 italic>位置缩小到约160千碱基。接下来,构建了细菌人工染色体(BAC)重叠群。最后,对选择的BAC进行测序,以鉴定候选基因,然后通过Northern和DNA序列分析对表达或序列差异进行分析。在HcB-19 / Dem italic>中,观察到先前描述为维生素D 3 sub>上调蛋白1( Vdup1 italic>)的基因的mRNA水平降低。 。 Vdup1 italic> RT-PCR产物的测序表明,高脂血症性HcB-19 / Dem italic>菌株中存在无意义的突变,而正常血脂异常对照菌株中则无此突变。没有发现任何其他候选基因的差异。 Vdup1蛋白,也称为硫氧还蛋白相互作用因子(Thif),结合并抑制硫氧还蛋白,硫氧还蛋白是一种具有二硫键还原活性的普遍存在的蛋白,在多种细胞过程中发挥作用。 HcB-19 / Dem italic>小鼠中的无意义突变发生在1456 bp cDNA(Genbank AF173681)的337位,对应于395个氨基酸蛋白的97位氨基酸。由于 Hyplip1 italic>的无义突变而截短的Vdup1将无法结合并抑制硫氧还蛋白,因为残基134-395对于这种相互作用至关重要。除了合并的高脂血症外,HcB-19 / Dem italic>小鼠还表现出高酮血症,低血糖症以及血浆乳酸,游离脂肪酸和未酯化胆固醇水平的升高。初步证据还表明对肝癌的敏感性增加。这些结果揭示了影响脂质和碳水化合物代谢的新型途径,具有潜在的临床意义。
展开▼